Coherus Biosciences (NASDAQ:CHRS) was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Monday, ValuEngine reports.

Other analysts have also recently issued research reports about the company. Zacks Investment Research upgraded Coherus Biosciences from a “hold” rating to a “buy” rating and set a $19.00 target price on the stock in a report on Monday. TheStreet raised shares of Coherus Biosciences from a “d+” rating to a “c-” rating in a report on Friday, March 20th. Credit Suisse Group reaffirmed a “buy” rating and issued a $36.00 target price on shares of Coherus Biosciences in a research note on Thursday, March 5th. SunTrust Banks began coverage on shares of Coherus Biosciences in a research report on Friday, April 17th. They set a “buy” rating and a $26.00 target price on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Coherus Biosciences in a report on Friday, May 8th. Two equities research analysts have rated the stock with a sell rating and eight have issued a buy rating to the company’s stock. Coherus Biosciences presently has a consensus rating of “Buy” and an average price target of $30.88.

Coherus Biosciences stock traded down $0.45 during trading hours on Monday, hitting $17.25. 2,192,900 shares of the stock were exchanged, compared to its average volume of 1,541,435. The stock has a market capitalization of $1.22 billion, a P/E ratio of 8.80 and a beta of 2.05. The business’s 50-day moving average is $17.46 and its two-hundred day moving average is $17.77. The company has a debt-to-equity ratio of 1.21, a quick ratio of 3.18 and a current ratio of 3.32. Coherus Biosciences has a 12 month low of $10.86 and a 12 month high of $23.91.

Coherus Biosciences (NASDAQ:CHRS) last announced its earnings results on Thursday, May 7th. The biotechnology company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.44 by $0.10. Coherus Biosciences had a return on equity of 190.82% and a net margin of 33.42%. The business had revenue of $116.18 million for the quarter, compared to the consensus estimate of $116.25 million. On average, equities analysts predict that Coherus Biosciences will post 1.31 earnings per share for the current fiscal year.

In other news, Director Mary T. Szela sold 54,997 shares of the stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $17.58, for a total value of $966,847.26. Following the transaction, the director now owns 14,997 shares of the company’s stock, valued at approximately $263,647.26. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Vincent R. Anicetti sold 5,000 shares of Coherus Biosciences stock in a transaction on Friday, April 17th. The stock was sold at an average price of $15.57, for a total value of $77,850.00. The disclosure for this sale can be found here. Insiders sold a total of 268,925 shares of company stock worth $4,627,867 in the last ninety days. Insiders own 15.86% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the business. Private Capital Group LLC grew its position in shares of Coherus Biosciences by 244.7% during the 1st quarter. Private Capital Group LLC now owns 2,382 shares of the biotechnology company’s stock worth $39,000 after buying an additional 1,691 shares during the period. Meeder Asset Management Inc. boosted its stake in Coherus Biosciences by 378.7% during the 4th quarter. Meeder Asset Management Inc. now owns 2,269 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 1,795 shares during the last quarter. Great West Life Assurance Co. Can acquired a new position in Coherus Biosciences during the fourth quarter valued at approximately $64,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Coherus Biosciences by 27.3% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,617 shares of the biotechnology company’s stock valued at $75,000 after purchasing an additional 990 shares in the last quarter. Finally, Advisor Group Holdings Inc. acquired a new stake in Coherus Biosciences in the first quarter worth $82,000.

Coherus Biosciences Company Profile

Coherus BioSciences, Inc, a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States.

Featured Story: What is total return in investing?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Coherus Biosciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.